Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Here's Why Select Medical (SEM) is an Attractive Bet Now

Published 06/16/2021, 01:34 AM
Updated 07/09/2023, 06:31 AM

Select Medical (NYSE:SEM) Holdings Corp. SEM is poised to grow on the back of its diversified business, improving top line, favourable cash flows, accretive acquisitions and partnership deal wins with various healthcare entities.

The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.4% upward over the past 30 days.

Year to date, the stock with a market capitalization of $5.8 billion has gained 54% compared with its industry’s growth of 14.2%.

Image Source: Zacks Investment Research

Let’s analyze some specific factors that help the stock stand out in its industry.

Solid VGM Score and Strong Zacks Rank: The company currently has a Zacks Rank #2 (Buy) and a VGM Score of A. Our research shows that stocks with a VGM Score of A or B combined with a Zacks Rank #1 or 2 or 3 (Hold) offer the best investment opportunities. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Increasing Top Line: The company’s revenues saw a CAGR of 9% from 2010 to 2020. The same was up 9.3% year over year in first-quarter 2021, courtesy of strength at the Critical Illness Recovery and Rehabilitation hospitals. Patient volumes are rising after remaining under pressure last year. This upside will aid revenues in turn.

Impressive Bottom Line: Along with a consistent top-line performance, the company’s bottom line did well too. Its earnings per share witnessed a CAGR of 14.6% from 2010 to 2020. This vouches for the company’s operational excellence. We believe that the company will be able to effectively manage its cost and deliver earnings growth.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Favorable Cash Flows: The company is constantly generating favorable adjusted cash flow from operations, which has been increasing consistently since 2017. The first quarter of 2021 also witnessed the metric rising more than five-fold year over year. This, in turn, has been helping it generate sufficient financial flexibility over time, enabling sufficient deployment of funds in the business. The company expects to generate free cash flows in the range of $450-$500 million a year.

Upbeat Guidance: Select Medical updated its business outlook for 2021. It expects full-year revenues in the $5.7-$5.9 billion range, higher than the prior guidance of $5.65-$5.85 billion band (indicating 5.5% growth from the 2020 reported figure). Adjusted EBITDA is forecast between $870 million and $900 million, up from the prior guidance of $840-$880 million (suggesting 10.5% growth from the 2020 reported figure). Earnings per common share are anticipated within $2.41-$2.58, above the previous guidance of $2.26-$2.48 (implying 29.3% jump from the prior-year reported number).

For the 2021-2023 time period, Select Medical is targeting a revenue CAGR of 4-6%, adjusted EBITDA in the 7-8% band and an EPS within 17-20%. Strong guidance instills investors’ confidence in the stock.
Consistent ROE: The company generated stability in its return on equity (ROE), which improved markedly from 2017 to 2020. As of Mar 31, 2021, its trailing 12-month ROE of 25.2% is higher than the industry’s ROE of 22.9%, reflecting its tactical efficiency in utilizing shareholders’ funds.

Other Stocks in the Healthcare Space

Other stocks in the healthcare space include Magellan Health (NASDAQ:MGLN), Inc. MGLN, The Joint Corp. JYNT and UnitedHealth Group Inc. UNH. All stocks presently carry the same bullish Zacks Rank as Select Medical.
For 2021, earnings at UnitedHealthcare, The Joint Corp. and Magellan Health are expected to grow 10.25%, 26.67% and 357.14%, respectively.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks' Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (NYSE:UNH): Free Stock Analysis Report

Magellan Health, Inc. (MGLN): Free Stock Analysis Report

Select Medical Holdings Corporation (SEM): Free Stock Analysis Report

The Joint Corp. (JYNT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.